FACACLASSIC

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”

HHS - 15124 - CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment - Authorized by Law

GENERAL INFORMATION

Committee Name	CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment	Agency Name	Department of Health and Human Services
Fiscal Year	2025	Committee Number	15124
Original Establishment Date	11/22/2002	Committee Status	Terminated
Actual Termination Date	4/1/2025	Committee URL	https://www.cdc.gov/faca/committees/chachspt.html
Actual Merged Date		Presidential Appointments*	No
New Committee This FY	No	Max Number of Members*	18
Terminated This FY	Yes	Designated Fed Officer Position Title*	DFO
Merged This FY		Designated Federal Officer Prefix
Current Charter Date	11/25/2024	Designated Federal Officer First Name*	Jonathan
Date Of Renewal Charter	11/25/2026	Designated Federal Officer Middle Name
Projected Termination Date	3/31/2025	Designated Federal Officer Last Name*	Mermin
Exempt From Renewal*	No	Designated Federal Officer Suffix	MD, MPH
Specific Termination Authority	E.O. 14217	Designated Federal Officer Phone*	(404) 639-8000
Establishment Authority*	Authorized by Law	Designated Federal Officer Fax*	404-639-8600
Specific Establishment Authority*	42 U.S.C. 217a	Designated Federal Officer Email*	jhm7@cdc.gov
Effective Date Of Authority*	11/17/1962
Exempt From EO 13875 Discretionary Cmte	Not Applicable
Committee Type*	Continuing
Presidential*	No
Committee Function*	Scientific Technical Program Advisory Board

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*	Terminate
Legislation to Terminate Required	Not Applicable
Legislation Status	Not Applicable
How does cmte accomplish its purpose?*	The Centers for Disease Control and Prevention (CDC) and Health Resources and Services Administration (HRSA) Advisory Committee on HIV, Viral Hepatitis and Sexually Transmitted Diseases (STD) Prevention and Treatment (CHAC) accomplished its purpose by deliberating and making recommendations to the U.S. Department of Health and Human Services (HHS) Secretary, the CDC Director, and the HRSA Administrator on timely topics relevant to the Committee’s focus. The Committee established workgroups to research and provide reports on objectives, strategies, policies, and priorities for HIV, viral hepatitis, and STD prevention and treatment efforts including (1) surveillance; (2) epidemiologic, behavioral, health services, and laboratory research; (3) identification of policy issues and opportunities related to prevention and treatment including but not limited to professional education, healthcare delivery, chronic conditions and comorbidities, research, and prevention and treatment services; (4) strategic issues influencing the ability of CDC and HRSA to fulfill their missions; (5) development and implementation of federal programs focused on prevention and treatment; and (6) providing support to the agencies in their response to emerging health needs.
How is membership balanced?*	CHAC’s membership was composed of recognized HIV, viral hepatitis, and STD experts in the fields of public health; epidemiology; laboratory practice; immunology; infectious diseases; substance use disorder; behavioral health; health education; healthcare delivery; state health programs; clinical care; preventive health; medical education; health services and clinical research; and healthcare financing. The Committee must include at least four members who were persons with HIV. The Committee membership may also include representation from persons with a history of viral hepatitis, STDs, and drug use; state and local health department employees; and staff from HIV, viral hepatitis, or STD community or faith-based organizations. CDC’s and HRSA’s recruitment processes ensured that the membership is balanced by geographic region, race/ethnicity, and expertise.
How frequent & relevant are cmte mtgs?*	CHAC typically convened committee meetings twice a fiscal year (FY). CHAC’s activities included holding regular meetings to discuss critical and timely issues, establishing workgroups to focus on specific topic areas, and presenting findings and outcomes to the CHAC. CHAC provided recommendations and advice to the HHS Secretary, HRSA Administrator, and CDC Director. The Committee provided direction and guidance to CDC, HRSA, and HHS on a variety of high priority topics related to HIV, viral hepatitis, and sexually transmitted diseases. CHAC convened once in FY 2025 on October 21-22, 2024 in Rockville MD. During the October 2024 committee meeting, members discussed topics including data-to-care strategies to re-engage people with HIV out of care, use of long-acting injectables (LAI) for HIV care and treatment, increasing access to mental health services for people with HIV and STDs, and overcoming barriers to re-engage people with HIV out of care. Members also voted to approve four recommendations for CDC and HRSA to support lifetime HIV survivors to (1) Include lifetime survivors in all HIV-related programming – Ryan White HIV/AIDS Program (RWHAP) and recipients, the Secretary’s HIV/AIDS Fund, Presidential Advisory Council on HIV/AIDS – and in the development of action plans, initiatives, and advisory committees of HHS; (2) Address long-term health outcomes for survivors (e.g., increased HIV mortalities, metabolic outcomes, mental health, fatigue, cancer, etc.) and include lifetime survivors as a separate category in studies and surveillance, including in National Institutes of Health-sponsored research and the RWHAP; (3) Establish different models of care and provider resource needs within HRSA-funded recipients that shares best practices, develops centers of excellence, and hubs of expertise; and (4) Develop a strategic plan, including specific goals and action steps within HHS, to address the unique needs, health outcomes, and quality of life of lifetime survivors of HIV. The CHAC Long Acting Injectable Workgroup (LAIWG) did not convene in FY 2025. During the October 2024 committee meeting, the LAIWG presented updates on its efforts to address LAI access and reimbursement challenges and emphasized the importance of incorporating people with HIV to inform policy and improve care delivery. The LAIWG also highlighted its collaboration with HRSA to organize the panel discussion on the perspectives of people with HIV on the use of LAIs for HIV care and treatment. After consideration of the LAIWG’s work, CHAC members deliberated and voted to approve two additional recommendations for CDC and HRSA to (1) Work with partners in clinical practice to seek feedback on the preferred mechanism for reimbursement of LAIs (pharmacy vs. medical benefit) for best patient access and to communicate this preference to the appropriate parties to seek standardization of LAIs under exclusively pharmacy or medical benefit and to eliminate cost sharing/co-pays; and (2) Work with the Food and Drug Administration (FDA) on potential labeling changes for LAIs to include viremic patients in alignment with current guidelines. The CHAC Community Partnerships Workgroup (CPWG) did not convene in FY 2025. During the October 2024 committee meeting, the CPWG did not report any updates and noted it completed its work during the Spring 2024 committee meeting. Following workgroup updates, members voted to sunset both the LAIWG and CPWG. Additionally, following panel discussions, members voted to form two new CHAC workgroups to (1) evaluate funding streams and models of care for point-of-care and self-testing for sexually transmitted infections and viral hepatitis; and (2) research payor levers that can be used to support services that are not funded by the RWHAP. On March 31, 2025, the CHAC was terminated in accordance with Executive Order (E.O.) 14217 entitled “Commencing the Reduction of the Federal Bureaucracy,”. No other Federal Advisory Committee addressing HIV, viral hepatitis, and sexually transmitted diseases currently exists. In response to CHAC recommendations, HHS issued five response letters in FY 2025. In November 2024, HHS issued the Self-Testing and Self-Collection and interim Syphilis Drug Shortage response letters. In December 2024, HHS issued the Youth Services response letter. Additionally, in January 2025, HHS issued the Harm Reduction and Syringe Services Programs response letter and CDC and HRSA issued the detailed Syphilis Drug Shortage response letter.
Why advice can't be obtained elsewhere?*	Every year, millions of Americans are diagnosed with HIV, viral hepatitis, and sexually transmitted infections (STIs). Specifically, In 2024, CDC reported over 38,000 individuals newly diagnosed with HIV in the U.S. Additionally, CDC reported over 11,000 Hepatitis C-related deaths, over 1,700 Hepatitis B-related deaths, and more than 2.4 million cases of STIs in the U.S in 2023. The work of CHAC was important in assisting CDC and HRSA achieve their missions related to these conditions. As a joint CDC and HRSA committee, CHAC played a critical role ensuring an integrated approach to the prevention, care and treatment of HIV, viral hepatitis, and STDs. This unique composition allowed for a unified approach to the national HIV, viral hepatitis, and STD agenda, including providing support for the Ending the HIV Epidemic in the U.S. initiative, STI National Strategic Plan, Viral Hepatitis National Strategic Plan, and HRSA and CDC programs.
Why close or partially close meetings?	N/A
Recommendation Remarks	2025 Secretary Directive-Elimination of Federal Advisory Committees Within the Department of Health and Human Services, Terminated 04.01.2025. EO 14217 Reducing the Scope of the Federal Bureaucracy. CHAC does not produce reports.

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*	Yes	Action Reorganize Priorities*	Yes
Outcome Trust In Government	Yes	Action Reallocate Resources	Yes
Outcome Major Policy Changes	Yes	Action Issued New Regulations	No
Outcome Advance In Scientific Research	Yes	Action Proposed Legislation	No
Outcome Effective Grant Making	No	Action Approved Grants Or Other Payments	No
Outcome Improved Service Delivery	Yes	Action Other	No
Outcome Increased Customer Satisfaction	Yes	Action Comment	The agencies worked closely with the Committee Co-Chairs to identify priorities and issues to be addressed at committee meetings. Prior to the meetings, the agencies prepared agendas and provided background materials to Advisory Committee members. As needed, the agencies also supported workgroups formed by CHAC members, which include presentation by outside experts, to focus on priority issues under the scope of the Advisory Committee.
Outcome Implement Laws/Reg Requirements	Yes	Grants Review*	No
Outcome Other	No	Number Of Grants Reviewed	0
Outcome Comment	N/A	Number Of Grants Recommended	0
Cost Savings*	Unable to Determine	Dollar Value Of Grants Recommended	$0.00
Cost Savings Comment	There was no apparent cost-savings in comparison to the previous year.	Grants Review Comment	N/A
Number Of Recommendations*	261	Access Contact Designated Fed. Officer*	Yes
Number Of Recommendations Comment	CHAC recommendations issued in FY 2025 fell under the categories of supporting lifetime HIV survivors and reimbursement and labeling of long-acting injectable drugs for HIV.	Access Agency Website	Yes
% of Recs Fully Implemented*	71.00%	Access Committee Website	Yes
% of Recs Fully Implemented Comment	Since 2007, 171 recommendations were fully implemented.	Access GSA FACA Website	Yes
% of Recs Partially Implemented*	16.00%	Access Publications	No
% of Recs Partially Implemented Comment	Since 2007, 39 recommendations remain partially implemented. We work with programs on a routine basis to update partially implemented recommendations. Currently 31 recommendations have not been implemented by the agencies.	Access Other	No
Agency Feedback*	Yes	Access Comment	Information for On line Committee Web Site can be found at SBI website: https://www.cdc.gov/faca/committees/chachspt.html
Agency Feedback Comment*	Feedback was provided to the CHAC at committee meetings: by written and electronic correspondence; and in reports and recommendations which were published in CDC’s Morbidity and Mortality Weekly Reports.	Narrative Description*	The Committee supported the missions of the CDC and HRSA by providing recommendations on important issues related to the prevention, control, and treatment of HIV, viral hepatitis and STDs, and the support of health care and treatment services to people with HIV.

COSTS

1. Payments to Non-Federal Members*		1. Est Paymnts to Non-Fed Membrs Nxt FY*	$0.00
2. Payments to Federal Members*		2. Est. Payments to Fed Members Next FY*	$0.00
3. Payments to Federal Staff*		3. Estimated Payments to Federal Staff*	$0.00
4. Payments to Consultants*		4. Est. Payments to Consultants Next FY*	$0.00
5. Travel Reimb. For Non-Federal Membrs*		5. Est Travel Reimb Non-Fed Membr nxtFY*	$0.00
6. Travel Reimb. For Federal Members*		6. Est Travel Reimb For Fed Members*	$0.00
7. Travel Reimb. For Federal Staff*		7. Est. Travel Reimb to Fed Staf Nxt FY*	$0.00
8. Travel Reimb. For Consultants*		8. Est Travel Reimb to Consltnts Nxt FY*	$0.00
10. Other Costs		10. Est. Other Costs Next FY*	$0.00
11. Total Costs	$0.00	11. Est. Total Next FY*	$0.00
Date Cost Last Modified	3/14/2025 9:51 AM	Est. Fed Staff Support Next FY*	0.00
Federal Staff Support (FTE)*		Est Cost Remarks	The Committee was terminated effective March 31, 2025, under E.O. 14217, Commencing the Reduction of the Federal Bureaucracy.
Cost Remarks

Interest Areas

Category Area Health Health Care Public Health Treatment Medicine Diseases Health and Health Research Illnesses

Custom Links

Committee Level Reports